Health and Disease in the Retinas and Optic Nerves—for Up-to-Date Practitioners
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Ophthalmology".
Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 16652
Special Issue Editors
Interests: genesis and molecular mechanism of therapies in ocular diseases, especially retinal diseases, caused by genetic mutations, aging, and drug side effects; clinical trials of different therapies in ocular diseases, which are evaluated by functional and morphological exams
Special Issues, Collections and Topics in MDPI journals
Interests: understanding the pathophysiology of glaucoma using a multidisciplinary approach; translational medicine research
Interests: intraocular inflammation and secondary acquired retinal degeneration; surgical retinal procedure-related innovations
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Recent research indicates that many factors, including genetic mutations, aging, and drug side effects, affect ocular cells and tissues. These diseases are often caused by mutations encoding many different signaling and structural proteins. The devastating effects of these diseases are substantial as they are often associated with several comorbidities, leading to a poor quality of life. Although many factors and mechanisms for some of these diseases have already been identified, the mechanisms regulating the development of ocular diseases are not fully understood, and novel therapies are warranted.
In this Special Issue, we welcome researchers and clinicians to contribute with Original Research and Review articles describing their in vitro and/or in vivo data, as well as clinical studies, to address the mechanisms by which genetic factors and protein molecules regulate ocular disorders, as well as novel diagnostic technologies and therapies for those diseases. Clinical Report is NOT accepted. The following topics are particularly welcome:
- The potential effect of genetic mutations, aging, and drug side effects on eye diseases, including studies on novel mutations/biomarkers and signaling pathways.
- Novel technologies, such as electrophysiology, spectral domain optical coherence tomography, optical coherence tomography angiography, artificial intelligence, clinical molecular genetic tests, etc., for diagnosis and monitoring of those eye diseases in the aspects of functional, morphological, and molecular characterization;
- Therapeutic interventions for eye diseases, including drug, surgery, stem cell, cell, and gene therapies.
Submission Guideline:
1. type: research article/review/communication are welcomed, for theses retrospective/cohort/follow-up, narrative review, preliminary study, system/meta-analysis, health care/nursing, prediction/prognostic indicators/score/scale
2. case study/case series/study protocol are not considered, mini review/brief report/simple study, wait for the precheck approval first;
3. not considered topic, including clinical education, medical device/system/platform (Dentistry is ok), cadaver study, in-vitro (cell lines and with clinical significance are excluded), textbook review, medicine cost, tobacco/alcohol, 3D print of stomatology filed and without clinical application, survey or questionnaire of clinical psychology filed.
4. for plan paper with company affiliation, if only promote the company product, will reject, otherwise, can be considered, and also need provide conflicts of interest.
Dr. Minzhong Yu
Dr. Rachida Bouhenni
Prof. Shree K Kurup
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gene
- protein
- cell
- eye
- therapy
- diagnosis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.